Magellan Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Magellan Biosciences's estimated annual revenue is currently $3.9M per year. 0
- Magellan Biosciences's total funding is $50M.
Employee Data
- 00
Magellan Biosciences's People
| Name | Title | Email/Phone |
|---|---|---|
1 | COO | Reveal Email/Phone |
2 | Director Sales | Reveal Email/Phone |
3 | Dir Finance | Reveal Email/Phone |
Magellan Biosciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Magellan Biosciences?
Magellan Biosciences develops advanced instruments, automated systems, point-of-care products, and consumables for biomedical research and clinical diagnostics worldwide. These tools enable scientists and clinicians to produce better, more-reliable results. And improved results help drive better outcomes -- a new understanding of health and disease, earlier, more-accurate diagnoses -- breakthrough discoveries that can lead to novel treatments, new cures -- innovations to enhance life.
keywords:N/A
$50M
Total Funding
N/A
Number of Employees
$3.9M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Magellan Biosciences News
... acquisition was performed on a FACSCanto system (BD Biosciences). ... The SparkControl Magellan software v.2.2 was used for data...
Rhythm Biosciences (RHY) ... This wholly owned subsidiary of Magellan Financial Group invests in global equities and global listed...
Magellan Biosciences Inc. tapped Hiroshi Uchida, the former technology chief for Fenwal Inc., to be its new president and CEO. The Chelmsford, Mass.-based diagnostics firm said Uchida was instrumental in the carve-out of Fenwal from former parent Baxter International (NYSE:BAX) in 2007. The blo ...
Other Companies in North Billerica
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.9M | 6 | -14% | N/A |
#2 | $1.8M | 10 | -9% | N/A |
#3 | $1.6M | 13 | -7% | N/A |
#4 | $1.3M | 15 | -12% | N/A |
#5 | $4.9M | 24 | -17% | N/A |